The global economic crisis and rising healthcare costs are making pricing and reimbursement for medical devices an increasingly delicate balancing act. European countries, whose healthcare is mostly state-funded, are finding it ever more challenging to meet the needs of a growing elderly population. In parallel, new healthcare legislation in the USA, will see payers, employers, and group purchasing organisations reigning in health care costs. Hospitals will negotiate harder for better prices on medical devices as DRG payments for procedures continue to shrink and their own costs continue to rise.Worldwide, governments are instigating mechanisms to limit or lower prices of prescription medicines.Traditional approaches to pricing and reimbursement strategy are now no longer sufficient. Life sciences manufacturers need a more rigorous and strategic approach to defend product prices and prevent revenue leakage in the face of heavy competition. Innovative manufacturers that evolve the next stage of pricing maturity will extract the greatest value in this changing environment. This next generation is one that is highly strategic, data-driven, global in nature, and integrated across pricing, product management and contracting.Stay ahead of market forces and • Assign monetary value to innovative medical devices and diagnostic technologies  • Maximise the value of CED from a device manufacturer perspective • Access market funding for medical devices in Central & Eastern Europe • Combine reimbursement and clinical expertise to realise clinical utility targets • Evaluate reimbursement mechanisms in the five leading EU markets, the USA and Japan